Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
NCT02332512 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- October 31, 2017
- Enrollment
- 417 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.